Primary hepatic large B-cell lymphoma

Arker, Soe Htet; Chen, Anne

doi:10.1016/j.hpr.2022.300653

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NHL is a lymphoid malignancy with variable biological and clinical symptoms, involving the lymphoid and hematopoietic systems [ 10 ]. The most common presenting signs and symptoms are abdominal pain and hepatomegaly with fever, weight loss, jaundice, fatigue, and night sweats [ 11 ]. DLBCL is the most common type of NHL worldwide, accounting for 30–40% of all NHL cases.…”

Section: Discussionmentioning

confidence: 99%

Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy

et al. 2022

View full text Add to dashboard Cite

Non-Hodgkin’s lymphoma (NHL) is the fifth most common hematologic disorder in the United States, and its prevalence has been rising in Western countries. Among the subtypes of NHL, diffuse large B-cell lymphoma (DLBCL) mostly involves the lymph nodes, stomach, and gastrointestinal tract, whereas hepatic involvement of DLBCL is rare. On serologic testing, elevated immunoglobulin G (IgG) levels can be observed in DLBCL; however, elevated IgG levels are mainly observed in autoimmune hepatitis. A targeted-lesion biopsy is required for the diagnosis of DLBCL. Based on a final diagnosis, the patient was treated with rituximab-based chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP). Herein, we report a case of DLBCL mimicking antinuclear antibody-negative autoimmune hepatitis, which was finally diagnosed as DLBCL involving the liver, and was confirmed by liver biopsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Diffuse large B cell lymphoma (DLBCL) is the most common type of NHL worldwide, comprising 30%-40% of cases. 2,5,6 Liver involvement as a secondary complication is observed in a significant proportion of cases, affecting 16%-46% of patients during the disease's progression. 7 Numerous studies have elucidated the link between chronic inflammatory states, such as those seen in acute infections (e.g., hepatitis C virus [HCV]) and autoimmune disorders, and the emergence of primary hepatic lymphoma (PHL) through hepatic B cells.…”

Section: Introductionmentioning

confidence: 99%

“…Diffuse large B cell lymphoma (DLBCL) is the most common type of NHL worldwide, comprising 30%–40% of cases. 2 , 5 , 6 Liver involvement as a secondary complication is observed in a significant proportion of cases, affecting 16%–46% of patients during the disease's progression. 7 …”

Section: Introductionmentioning

confidence: 99%

Primary Hepatic EBV-DLBCL Lymphoma in the Setting of COVID-19 Infection

De Souza,

Ismail,

Elaskandrany

et al. 2024

ACG Case Rep J

View full text Add to dashboard Cite

This case study describes an instance of primary hepatic diffuse large B cell lymphoma (DLBCL) in a patient who had prolonged coronavirus disease 2019 (COVID-19). DLBCL rarely presents as a primary hepatic mass. The 53-year-old man sought emergency care because of fatigue and weight loss. Diagnostic tests showed mildly elevated liver enzymes and imaging pointed to several low-density liver lesions. A liver biopsy paired with immunohistochemical testing verified the DLBCL diagnosis. Notably, the patient had COVID-19 4 months before the liver-related symptoms. The link between COVID-19 and the emergence of solid tumor cancers is unclear, but this case underscores its potential significance and the need for further research. This report stresses the importance of recognizing and documenting instances where COVID-19 might influence the onset of solid tumor cancers, including primary hepatic DLBCL.

show abstract

Primary extra – nodal DLBCL at rare sites: A case series

Vijayakumar,

Kuruvilla,

Parameswaran

et al. 2024

IJPO

View full text Add to dashboard Cite

: Lymphomas can originate from either nodal or extra-nodal sites, with an increasing number of patients presenting with extra-nodal non-Hodgkin's lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of primary extra-nodal NHL, constituting 71–81.3% of cases. DLBCL, a prevalent aggressive NHL, can manifest in various extranodal locations such as the gastrointestinal tract, thyroid, testis, breast, and skin. It can also originate in lymph nodes before spreading to extranodal sites. The heterogeneity of extranodal DLBCL leads to varied clinical presentations and prognoses depending on the affected organs.: This case series examines instances of primary extra-nodal DLBCL occurring at rare sites. Through detailed clinical evaluations and pathological examinations, the series aims to highlight the diagnostic challenges and therapeutic approaches for these uncommon presentations. In this case series we have described primary extra-nodal DLBCL in rare sites like thyroid, cervix, liver, breast and intraventricular region. Each case is meticulously documented, focusing on the patient's clinical history, the site of lymphoma involvement, diagnostic procedures, treatment modalities, and outcomes.: The discussion addresses the complexities of diagnosing primary extra-nodal DLBCL due to its rarity and diverse presentation. The series underscores the importance of thorough clinical and pathological assessments in identifying these cases. The heterogeneity in clinical outcomes emphasizes the need for tailored therapeutic strategies. Moreover, the series explores the immunohistochemical profiles and genetic markers that might aid in better understanding the disease's behavior and improving patient management. Primary extra-nodal DLBCL at rare sites presents significant diagnostic and therapeutic challenges. This case series contributes valuable insights into the clinical and pathological spectrum of the disease, advocating for personalized treatment approaches to enhance patient outcomes.

show abstract

Primary hepatic large B-cell lymphoma

Cited by 3 publications

References 29 publications

Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy

Hepatic Involvement of Diffuse Large B-Cell Lymphoma Mimicking Antinuclear Antibody-Negative Autoimmune Hepatitis Diagnosed by Liver Biopsy

Primary Hepatic EBV-DLBCL Lymphoma in the Setting of COVID-19 Infection

Primary extra – nodal DLBCL at rare sites: A case series

Contact Info

Product

Resources

About